Acute Myeloid Leukemia (AML), an aggressive form of blood cancer, has long been a significant challenge for patients and doctors in India. But recent medical breakthroughs—including the recent approva ...

"Ivosidenib is the first targeted therapy developed specifically for AML patients who carry the rare IDH1 gene mutation," said Dr Melinkeri.

Final results from ClarIDHy, a global, phase 3, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an ...

Ivosidenib (Tibsovo ®) is a type of targeted therapy drug called a cancer growth inhibitor. Azacitidine is a chemotherapy drug. Ivosidenib and azacitidine treatment is used to treat acute myeloid ...